Trials / Recruiting
RecruitingNCT05068232
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer (DARES)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Ablative Radiation | Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs. |
| DRUG | Durvalumab | Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer. |
| DRUG | Etoposide | Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer. |
| DRUG | Carboplatin | Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer. |
Timeline
- Start date
- 2022-08-19
- Primary completion
- 2027-10-01
- Completion
- 2027-10-01
- First posted
- 2021-10-05
- Last updated
- 2026-03-04
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05068232. Inclusion in this directory is not an endorsement.